동물 통증 관리 시장 보고서 : 제품, 동물 유형, 용도, 최종사용자, 지역별(2025-2033년)

The global veterinary pain management market size reached USD 1.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.7 Billion by 2033, exhibiting a growth rate (CAGR) of 5.63% during 2025-2033. There are several factors that are driving the market, which include the rising number of pet parents, various regulatory approvals, and increasing prevalence of chronic diseases such as arthritis, cancer, joint pain, and post-surgical pain.

Veterinary pain management refers to various drugs and drug combinations administered to animals for providing relied from chronic pain. It involves the observation of behavioral cues and anticipating the type, severity and duration of the pain. The treatment involves physical compresses, massages, therapy, rehabilitation, acupuncture, laser therapy and the administration of therapeutic and antianxiety drugs. These drugs can be administered orally, parenterally or topically. Veterinary pain management involves implementing changes in housing conditions, diet and level of interaction with other animals and humans. It is effective against acute surgical, traumatic and disease-related pain and also aids in improving the overall health of the animal.

Veterinary Pain Management Market Trends:

The increasing domestication of animals, along with the rising awareness regarding pet health among the masses, is one of the key factors driving the growth of the market. Moreover, the convenient availability of pain management products and devices, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), laser devices and local anesthetics, is providing a thrust to the market growth. These solutions provide relief from the pain caused by musculoskeletal disorders, radiotherapy-induced pain, chemotherapy, osteoarthritis and mastitis. In line with this, the widespread adoption of laser therapy as an effective solution for pain management is also contributing to the market growth. Laser therapy provides significant pain-relief and also aids in regenerating nerve tissue post-surgery. Additionally, a significant increase in the livestock population suffering from cancer, abdominal and neuropathic pain is also creating a positive outlook for the market. Other factors, including the rising prevalence of inflammation and pain-causing diseases in domesticated animals, along with the widespread adoption of pet insurance services, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Product:

• Drugs
• NSAIDs
• Anesthetics
• Opioids
• Other Drugs
• Devices
• Laser Therapy
• Electromagnetic Therapy

Breakup by Animal Type:

• Companion
• Livestock

Breakup by Application:

• Osteoarthritis and Joint Pain
• Postoperative Pain
• Cancer
• Others

Breakup by End User:

• Hospitals and Clinics
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Assisi Animal Health, Bayer AG, Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Ceva Sante Animale, Chanelle Pharma, Dechra Pharmaceuticals PLC, Eli Lilly and Company, Idexx Laboratories Inc., Merck & Co. Inc., Norbrook, Vetoquinol S.A. and Zoetis Inc.

Key Questions Answered in This Report

• 1.How big is the global veterinary pain management market?
• 2.What is the expected growth rate of the global veterinary pain management market during 2025-2033?
• 3.What are the key factors driving the global veterinary pain management market?
• 4.What has been the impact of COVID-19 on the global veterinary pain management market?
• 5.What is the breakup of the global veterinary pain management market based on the product?
• 6.What is the breakup of the global veterinary pain management market based on the application?
• 7.What is the breakup of the global veterinary pain management market based on the end user?
• 8.What are the key regions in the global veterinary pain management market?
• 9.Who are the key players/companies in the global veterinary pain management market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Veterinary Pain Management Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Drugs
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 NSAIDs
    • 6.1.2.2 Anesthetics
    • 6.1.2.3 Opioids
    • 6.1.2.4 Other Drugs
  • 6.1.3 Market Forecast
• 6.2 Devices
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Laser Therapy
    • 6.2.2.2 Electromagnetic Therapy
  • 6.2.3 Market Forecast

7 Market Breakup by Animal Type

• 7.1 Companion
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Livestock
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Osteoarthritis and Joint Pain
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Postoperative Pain
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Cancer
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals and Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Others
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Assisi Animal Health
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Bayer AG
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Ceva Sante Animale
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Chanelle Pharma
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Dechra Pharmaceuticals PLC
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Eli Lilly and Company
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Idexx Laboratories Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Merck & Co. Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Norbrook
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 Vetoquinol S.A.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
  • 15.3.12 Zoetis Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis